Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Med (New York, N.Y.)|May 17, 2025
Advances in TIL therapy: Expanding the horizons beyond melanomaPauline Wiertsema, Ya Hwee Tan, John B A G Haanen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 18, 2009
Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapyMaarten L Zandvliet, J H Frederik Falkenburg, Inge Jedema, et al.
Blood|November 25, 2003
New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell populationInge Jedema, Nicole M van der Werff, Renée M Y Barge, et al.
European Journal of Haematology|August 5, 2018
Immune surveillance by autoreactive CD4-positive helper T cells is a common phenomenon in patients with acute myeloid leukemiaTin Sing Lam, Marian van de Meent, Erik W A Marijt, et al.
Leukemia & Lymphoma|February 1, 2017
Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitorsFloris C Loeff, H M Esther van Egmond, Bart A Nijmeijer, et al.
Frontiers in Immunology|April 15, 2021
Magnitude of Off-Target Allo-HLA Reactivity by Third-Party Donor-Derived Virus-Specific T Cells Is Dictated by HLA-RestrictionWesley Huisman, Didier A T Leboux, Lieve E van der Maarel, et al.
Haematologica|May 7, 2011
Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cellsInge Jedema, Marian van de Meent, Jeanette Pots, et al.
European Journal of Immunology|October 3, 2022
Amino acids at position 5 in the peptide/MHC binding region of a public virus-specific TCR are completely inter-changeable without loss of functionWesley Huisman, Melanie de Gier, Lois Hageman, et al.
Haematologica|December 17, 2013
A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cellsMarleen M van Loenen, Renate de Boer, Ellis van Liempt, et al.
Nature Reviews. Nephrology|July 22, 2025
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitorsFemke H Burgers, Johannes C K van der Mijn, Tom T P Seijkens, et al.
Pageof 7